Has Rebecca Lehman received payments from drug or device companies?

Yes. Drug and device makers reported $6,712 in general payments to Rebecca Lehman across 26 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rebecca Lehman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rebecca Lehman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rebecca Lehman

Neurology with Special Qualifications in Child Neurology · Columbia, SCNPI 1831105659

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,268 of the $6,712 with a category attached, or 63.6%. Teva Pharmaceuticals USA, Inc. accounts for 83.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $5,698 and has fallen 99.7% since, to $18 in 2025. Among neurology with special qualifications in child neurology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,712in general payments, 2019–2025

Across 26 payments — averaging $258.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$6K
Abbott$342
Medtronic$264
Biogen$195
Spinal Simplicity, LLC$182
UCB, Inc.$95
plus $50 from 3 others

$428,979in research payments, 2019–2025

Across 86 payments — averaging $4988.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Teva Pharmaceuticals USA, Inc.$254K
AbbVie$138K
Eli Lilly$25K
Biohaven Pharmaceutical Holding Company Ltd.$9K
Pfizer$4K

What the payments were for

Consulting fees$4,26864%
Travel & lodging$1,12617%
Food & beverage$1,31020%
Education$80%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	5	$5,585
Abbott	4	$342
Medtronic(2 entities)	2	$264
Biogen	2	$195
Spinal Simplicity, LLC	4	$182
UCB, Inc.	2	$95
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	1	$24
Novartis	1	$18
Travere Therapeutics, Inc.	5	$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,712 in reported general payments places this provider in the 95th percentile of 25 neurology with special qualifications in child neurology providers in South Carolina.

See all neurology with special qualifications in child neurology providers in South Carolina →

Other neurology with special qualifications in child neurology in Columbia

Ramit SinglaColumbia$1K
Mary GregoryColumbia$783
Jordann StaplesColumbia$562
Matthew KhayataColumbia$423
Krisztina Harsanyi-JillingColumbia$255
James ParrottColumbia$54
Dalila LewisCharleston$113K
Mariana SzuchmacherCharleston$7K
Robert TurnerCharleston$2K
Michael BabcockGreenville$2K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →